AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and What's Actually Changing in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and What's Actually Changing in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and What's Actually Changing in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.